HTF Market Intelligence released a new research report of 151 pages on title ‘Hemophilia A – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers key regions and important players such as Expression Therapeutics LLC, Green Cross Corp, Idogen AB etc.
Request a sample report @ https://www.htfmarketreport.com/sample-report/437105-hemophilia-a-pipeline-review
The latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A – Pipeline Review, H1 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.
Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.
The Pharmaceutical and Healthcare latest pipeline guide Hemophilia A – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 6, 5, 1, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
– The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=437105
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Alnylam Pharmaceuticals Inc
Amarna Therapeutics BV
Apitope International NV
BioMarin Pharmaceutical Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
DBV Technologies SA
Dimension Therapeutics Inc
Emergent BioSolutions Inc
Expression Therapeutics LLC
Green Cross Corp
Lentigen Technology Inc
Novo Nordisk A/S
OPKO Biologics Ltd
Pangen Biotech Inc.
Pharming Group NV
Promethera Biosciences SA
rEVO Biologics Inc
Sangamo Therapeutics Inc
SK Chemicals Co Ltd
Spark Therapeutics Inc
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/437105-hemophilia-a-pipeline-review
Table of Contents
List of Tables 4
List of Figures 5
The Report Coverage 6
Hemophilia A – Overview 7
Hemophilia A – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Hemophilia A – Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Hemophilia A – Companies Involved in Therapeutics Development 25
Alnylam Pharmaceuticals Inc 25
Amarna Therapeutics BV 25
Apitope International NV 25
Bayer AG 26
BioMarin Pharmaceutical Inc 26
Bioverativ Inc 27
Catalyst Biosciences Inc 27
Chugai Pharmaceutical Co Ltd 28
CSL Ltd 28
DBV Technologies SA 29
Dimension Therapeutics Inc 29
Emergent BioSolutions Inc 30
EpiVax Inc 30
Expression Therapeutics LLC 31
Green Cross Corp 31
Idogen AB 32
Immusoft Corp 32
Lentigen Technology Inc 32
mAbxience SA 33
Novo Nordisk A/S 33
OPKO Biologics Ltd 34
Pangen Biotech Inc. 34
Pfizer Inc 34
Pharming Group NV 35
Promethera Biosciences SA 35
rEVO Biologics Inc 36
Sangamo Therapeutics Inc 36
Shire Plc 36
SK Chemicals Co Ltd 37
Spark Therapeutics Inc 38
UniQure NV 38
XL-protein GmbH 39
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/437105-hemophilia-a-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218